[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-001", "question": "A 74-year-old man presents with heart failure with preserved ejection fraction (HFpEF) and bilateral carpal tunnel syndrome. Echocardiography reveals a granular 'sparkling' appearance of the myocardium and increased wall thickness. A technetium-99m pyrophosphate (PYP) scan shows Grade 3 cardiac uptake (uptake > rib uptake). Serum immunofixation reveals a small IgG lambda monoclonal protein, and serum free light chain ratio is 1.8. Which of the following is the most appropriate next step in management to confirm the diagnosis?", "options": ["Initiate tafamidis therapy", "Perform TTR genetic testing", "Endomyocardial biopsy", "Abdominal fat pad aspiration", "Initiate bortezomib, cyclophosphamide, and dexamethasone"], "answer": "C", "answer_index": 2, "explanation": "While Grade 2/3 PYP uptake is highly specific for ATTR cardiac amyloidosis, this specificity drops significantly in the presence of a monoclonal gammopathy (MGUS). AL amyloidosis can occasionally show uptake on PYP scans. Therefore, in a patient with a positive PYP scan AND a monoclonal protein, a tissue biopsy (endomyocardial is gold standard if non-cardiac biopsy is negative or to avoid sampling error) is mandatory to distinguish ATTR from AL amyloidosis before starting treatment.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 74-year-old man with classic cardiac amyloidosis features (HFpEF, bilateral CTS, granular sparkling myocardium, increased wall thickness, Grade 3 PYP uptake). The critical discriminating finding is the presence of a monoclonal protein (IgG lambda) with abnormal free light chain ratio (1.8, outside normal 0.26-1.65). Key teaching point: Grade 2-3 PYP uptake is highly specific for ATTR amyloidosis in the absence of monoclonal protein, but this specificity is lost when monoclonal gammopathy is present, as AL amyloidosis can occasionally show PYP uptake. The keyed answer (C, endomyocardial biopsy) is correct because tissue diagnosis is mandatory to distinguish ATTR from AL amyloidosis before initiating treatment—these require completely different therapies (tafamidis for ATTR vs chemotherapy for AL). Option A (tafamidis) would be premature without confirming ATTR. Option B (TTR testing) assumes ATTR but doesn't exclude AL. Option D (fat pad) has lower sensitivity than endomyocardial biopsy and may miss cardiac-limited disease. Option E (chemotherapy) assumes AL without confirmation. No logical flaws; single best answer clearly supported. Medical accuracy is excellent, reflecting current diagnostic algorithms for cardiac amyloidosis with concurrent monoclonal gammopathy. Minimal fix: none needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 74-year-old man with classic cardiac amyloidosis features (HFpEF, bilateral CTS, granular sparkling myocardium, increased wall thickness, Grade 3 PYP uptake). The critical discriminating finding is the presence of a monoclonal protein (IgG lambda) with abnormal free light chain ratio (1.8, outside normal 0.26-1.65). Key teaching point: Grade 2-3 PYP uptake is highly specific for ATTR amyloidosis in the absence of monoclonal protein, but this specificity is lost when monoclonal gammopathy is present, as AL amyloidosis can occasionally show PYP uptake. The keyed answer (C, endomyocardial biopsy) is correct because tissue diagnosis is mandatory to distinguish ATTR from AL amyloidosis before initiating treatment—these require completely different therapies (tafamidis for ATTR vs chemotherapy for AL). Option A (tafamidis) would be premature without confirming ATTR. Option B (TTR testing) assumes ATTR but doesn't exclude AL. Option D (fat pad) has lower sensitivity than endomyocardial biopsy and may miss cardiac-limited disease. Option E (chemotherapy) assumes AL without confirmation. No logical flaws; single best answer clearly supported. Medical accuracy is excellent, reflecting current diagnostic algorithms for cardiac amyloidosis with concurrent monoclonal gammopathy. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-002", "question": "A 24-year-old male presents with recurrent fevers, livedo racemosa, and acute left hemiparesis. MRI shows a lacunar infarct in the internal capsule. Angiography reveals a 'beads-on-a-string' appearance in the mesenteric and renal arteries. Laboratory evaluation shows low serum IgM and IgG levels. Genetic testing confirms a biallelic loss-of-function mutation in ADA2. Which of the following is the most appropriate maintenance therapy?", "options": ["Cyclophosphamide", "Rituximab", "Etanercept", "Prednisone monotherapy", "Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "The patient has Deficiency of Adenosine Deaminase 2 (DADA2), which mimics Polyarteritis Nodosa (PAN) but is distinct due to its association with early-onset strokes and hypogammaglobulinemia. Unlike classic PAN, which is treated with cyclophosphamide, DADA2 is driven by TNF-alpha dysregulation. TNF inhibitors (like etanercept) are the treatment of choice and are highly effective in preventing recurrent strokes, whereas cyclophosphamide is often ineffective.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a young male with recurrent fevers, livedo racemosa, lacunar stroke, vasculitic angiographic findings ('beads-on-a-string'), hypogammaglobulinemia (low IgM/IgG), and confirmed biallelic ADA2 loss-of-function mutation—diagnostic of DADA2 (Deficiency of Adenosine Deaminase 2). Key discriminating findings are: (1) young age with stroke, (2) PAN-like vasculitis pattern, (3) hypogammaglobulinemia, and (4) genetic confirmation of ADA2 mutation. DADA2 pathophysiology involves TNF-α dysregulation, making TNF inhibitors (etanercept, C) the evidence-based maintenance therapy that prevents recurrent strokes and systemic vasculitis. Cyclophosphamide (A) is used for classic PAN but is ineffective in DADA2. Rituximab (B) addresses B-cell dysfunction but is not first-line for vasculitis control. Prednisone monotherapy (D) is insufficient for maintenance. Plasma exchange (E) has no role in DADA2. The keyed answer (C, etanercept) is uniquely defensible based on established DADA2 management guidelines. No logical flaws: stem provides sufficient detail, genetic confirmation eliminates diagnostic ambiguity, and only one option targets the disease mechanism. Medical accuracy is excellent—reflects current understanding of this monogenic autoinflammatory vasculopathy. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a young male with recurrent fevers, livedo racemosa, lacunar stroke, vasculitic angiographic findings ('beads-on-a-string'), hypogammaglobulinemia (low IgM/IgG), and confirmed biallelic ADA2 loss-of-function mutation—diagnostic of DADA2 (Deficiency of Adenosine Deaminase 2). Key discriminating findings are: (1) young age with stroke, (2) PAN-like vasculitis pattern, (3) hypogammaglobulinemia, and (4) genetic confirmation of ADA2 mutation. DADA2 pathophysiology involves TNF-α dysregulation, making TNF inhibitors (etanercept, C) the evidence-based maintenance therapy that prevents recurrent strokes and systemic vasculitis. Cyclophosphamide (A) is used for classic PAN but is ineffective in DADA2. Rituximab (B) addresses B-cell dysfunction but is not first-line for vasculitis control. Prednisone monotherapy (D) is insufficient for maintenance. Plasma exchange (E) has no role in DADA2. The keyed answer (C, etanercept) is uniquely defensible based on established DADA2 management guidelines. No logical flaws: stem provides sufficient detail, genetic confirmation eliminates diagnostic ambiguity, and only one option targets the disease mechanism. Medical accuracy is excellent—reflects current understanding of this monogenic autoinflammatory vasculopathy. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-003", "question": "A 64-year-old male presents with a 1-year history of progressive gait instability, dysarthria, and dysphagia. His wife reports he has severe insomnia, stridor during sleep, and acts out his dreams. Polysomnography confirms obstructive sleep apnea and complex behaviors during both REM and NREM sleep. MRI brain is unremarkable. Which of the following antibodies is most likely to be positive?", "options": ["Anti-Hu", "Anti-Ma2", "Anti-LGI1", "Anti-IgLON5", "Anti-DPPX"], "answer": "D", "answer_index": 3, "explanation": "Anti-IgLON5 disease is a distinct tauopathy characterized by a unique sleep disorder (parasomnias in both REM and NREM sleep, stridor, OSA) combined with bulbar dysfunction and gait instability. While Anti-Ma2 is associated with brainstem/diencephalic involvement and sleepiness, the specific combination of stridor, NREM parasomnias, and bulbar palsy is pathognomonic for Anti-IgLON5.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a 64-year-old male with progressive gait instability, dysarthria, dysphagia, severe insomnia, stridor during sleep, dream enactment, and polysomnography showing complex behaviors during both REM and NREM sleep with obstructive sleep apnea. Key discriminating findings are: (1) parasomnias in both REM and NREM sleep, (2) stridor during sleep, (3) bulbar dysfunction (dysarthria/dysphagia), (4) gait instability, and (5) unremarkable MRI. This constellation is pathognomonic for anti-IgLON5 disease, a distinct tauopathy with characteristic sleep disorder combining REM behavior disorder, NREM parasomnias, stridor, and OSA with bulbar and motor dysfunction. Anti-Hu (paraneoplastic encephalomyelitis) lacks this specific sleep phenotype. Anti-Ma2 causes brainstem encephalitis with sleepiness but not the NREM parasomnia/stridor combination. Anti-LGI1 causes limbic encephalitis with faciobrachial dystonic seizures and hyponatremia. Anti-DPPX causes CNS hyperexcitability with diarrhea and myoclonus. The keyed answer (D) is uniquely defensible based on the pathognomonic clinical triad. Medical accuracy is excellent; the clinical description matches current literature on anti-IgLON5 disease. No fix needed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 64-year-old male with progressive gait instability, dysarthria, dysphagia, severe insomnia, stridor during sleep, dream enactment, and polysomnography showing complex behaviors during both REM and NREM sleep with obstructive sleep apnea. Key discriminating findings are: (1) parasomnias in both REM and NREM sleep, (2) stridor during sleep, (3) bulbar dysfunction (dysarthria/dysphagia), (4) gait instability, and (5) unremarkable MRI. This constellation is pathognomonic for anti-IgLON5 disease, a distinct tauopathy with characteristic sleep disorder combining REM behavior disorder, NREM parasomnias, stridor, and OSA with bulbar and motor dysfunction. Anti-Hu (paraneoplastic encephalomyelitis) lacks this specific sleep phenotype. Anti-Ma2 causes brainstem encephalitis with sleepiness but not the NREM parasomnia/stridor combination. Anti-LGI1 causes limbic encephalitis with faciobrachial dystonic seizures and hyponatremia. Anti-DPPX causes CNS hyperexcitability with diarrhea and myoclonus. The keyed answer (D) is uniquely defensible based on the pathognomonic clinical triad. Medical accuracy is excellent; the clinical description matches current literature on anti-IgLON5 disease. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-004", "question": "A 68-year-old male presents with fever of unknown origin, 15 kg weight loss, and fatigue 4 years after undergoing aortic valve replacement. Labs reveal pancytopenia and elevated liver enzymes. TTE and TEE show no vegetations. PET-CT demonstrates hypermetabolic activity in the spleen and bone marrow. Bone marrow biopsy reveals non-caseating granulomas. Standard blood cultures are negative. Which of the following is the most likely etiology?", "options": ["Sarcoidosis", "Culture-negative endocarditis (HACEK group)", "Mycobacterium chimaera", "Tropheryma whipplei", "Late-onset prosthetic valve thrombosis"], "answer": "C", "answer_index": 2, "explanation": "This is the classic presentation of disseminated *Mycobacterium chimaera* infection associated with contaminated heater-cooler units used during cardiopulmonary bypass. The incubation period can be several years. It presents with systemic symptoms, cytopenias, and granulomatous inflammation (often misdiagnosed as sarcoidosis). Diagnosis requires specific mycobacterial blood cultures or tissue PCR.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem provides highly discriminating clues: (1) aortic valve replacement 4 years prior, (2) fever of unknown origin with constitutional symptoms, (3) pancytopenia and elevated liver enzymes, (4) negative standard blood cultures, (5) negative TEE for vegetations, (6) PET-CT showing hypermetabolic spleen/bone marrow, and (7) non-caseating granulomas on bone marrow biopsy. This constellation strongly suggests disseminated Mycobacterium chimaera infection, a recognized complication of contaminated heater-cooler units during cardiopulmonary bypass with characteristic delayed presentation (months to years post-surgery). Option A (sarcoidosis) lacks the cardiac surgery context and typically wouldn't present with pancytopenia. Option B (HACEK endocarditis) would more likely show vegetations on TEE. Option D (Tropheryma whipplei) causes Whipple disease with different clinical features (GI symptoms, CNS involvement). Option E (prosthetic valve thrombosis) wouldn't explain granulomas or systemic inflammation. The keyed answer C is medically accurate and represents the unique best answer given the specific post-cardiac surgery context with granulomatous disease and negative routine cultures. Minimal fix: None needed; item is well-constructed and discriminates appropriately.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem provides highly discriminating clues: (1) aortic valve replacement 4 years prior, (2) fever of unknown origin with constitutional symptoms, (3) pancytopenia and elevated liver enzymes, (4) negative standard blood cultures, (5) negative TEE for vegetations, (6) PET-CT showing hypermetabolic spleen/bone marrow, and (7) non-caseating granulomas on bone marrow biopsy. This constellation strongly suggests disseminated Mycobacterium chimaera infection, a recognized complication of contaminated heater-cooler units during cardiopulmonary bypass with characteristic delayed presentation (months to years post-surgery). Option A (sarcoidosis) lacks the cardiac surgery context and typically wouldn't present with pancytopenia. Option B (HACEK endocarditis) would more likely show vegetations on TEE. Option D (Tropheryma whipplei) causes Whipple disease with different clinical features (GI symptoms, CNS involvement). Option E (prosthetic valve thrombosis) wouldn't explain granulomas or systemic inflammation. The keyed answer C is medically accurate and represents the unique best answer given the specific post-cardiac surgery context with granulomatous disease and negative routine cultures. Minimal fix: None needed; item is well-constructed and discriminates appropriately.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-005", "question": "A 31-year-old female presents with amenorrhea 4 months after a full-term delivery. Ultrasound reveals a 4 cm echogenic mass in the myometrium. Serum beta-hCG is 120 IU/L. Immunohistochemistry of a biopsy specimen shows diffuse positivity for human placental lactogen (hPL) and Ki-67 index of 15%. Staging workup is negative for metastasis. What is the treatment of choice?", "options": ["Methotrexate and Folinic Acid", "Actinomycin D", "EMA-CO regimen", "Hysterectomy", "Pembrolizumab"], "answer": "D", "answer_index": 3, "explanation": "The diagnosis is Placental Site Trophoblastic Tumor (PSTT), distinguished from choriocarcinoma by low beta-hCG, strong hPL positivity, and origin from intermediate trophoblasts. Unlike choriocarcinoma, PSTT is relatively resistant to chemotherapy. For localized (Stage I) disease, hysterectomy is the primary and definitive treatment. Chemotherapy is reserved for metastatic or high-risk disease.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 31-year-old woman with postpartum amenorrhea, myometrial mass, low beta-hCG (120 IU/L), strong hPL positivity, and Ki-67 15%—classic for Placental Site Trophoblastic Tumor (PSTT). Key discriminating findings: (1) low beta-hCG relative to mass size, (2) diffuse hPL positivity (intermediate trophoblast marker), (3) localized disease (negative staging workup). PSTT is characteristically chemoresistant compared to choriocarcinoma. For Stage I PSTT, hysterectomy is the standard of care and curative. Option D (Hysterectomy) is correct. Option A (Methotrexate/Folinic Acid) and B (Actinomycin D) are single-agent regimens appropriate for low-risk gestational trophoblastic neoplasia (GTN) but not PSTT. Option C (EMA-CO) is multi-agent chemotherapy for high-risk GTN or metastatic disease, not first-line for localized PSTT. Option E (Pembrolizumab) is immunotherapy without established role in PSTT. The item is logically valid with a unique best answer matching the key. Medical accuracy is high, consistent with current GTN management guidelines. No fix needed; the question appropriately tests recognition of PSTT and its chemoresistance requiring surgical management.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 31-year-old woman with postpartum amenorrhea, myometrial mass, low beta-hCG (120 IU/L), strong hPL positivity, and Ki-67 15%—classic for Placental Site Trophoblastic Tumor (PSTT). Key discriminating findings: (1) low beta-hCG relative to mass size, (2) diffuse hPL positivity (intermediate trophoblast marker), (3) localized disease (negative staging workup). PSTT is characteristically chemoresistant compared to choriocarcinoma. For Stage I PSTT, hysterectomy is the standard of care and curative. Option D (Hysterectomy) is correct. Option A (Methotrexate/Folinic Acid) and B (Actinomycin D) are single-agent regimens appropriate for low-risk gestational trophoblastic neoplasia (GTN) but not PSTT. Option C (EMA-CO) is multi-agent chemotherapy for high-risk GTN or metastatic disease, not first-line for localized PSTT. Option E (Pembrolizumab) is immunotherapy without established role in PSTT. The item is logically valid with a unique best answer matching the key. Medical accuracy is high, consistent with current GTN management guidelines. No fix needed; the question appropriately tests recognition of PSTT and its chemoresistance requiring surgical management.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-006", "question": "A 40-year-old male with a known diagnosis of Brugada syndrome presents to the ER in electrical storm, having received 4 appropriate ICD shocks for ventricular fibrillation in the past hour. He is currently conscious but anxious. Vital signs are BP 110/70, HR 90. Which pharmacologic agent is most appropriate to suppress the arrhythmia?", "options": ["Intravenous Amiodarone", "Intravenous Lidocaine", "Intravenous Isoproterenol", "Intravenous Procainamide", "Intravenous Metoprolol"], "answer": "C", "answer_index": 2, "explanation": "In Brugada syndrome electrical storm, the goal is to decrease the ST-segment elevation and dispersion. Isoproterenol (a beta-agonist) increases heart rate and calcium current, normalizing the ST segment and suppressing VF. Quinidine is the oral alternative. Amiodarone, beta-blockers, and sodium channel blockers (Procainamide, Lidocaine) are contraindicated or ineffective as they can unmask or exacerbate the Brugada pattern.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 40-year-old male with Brugada syndrome in electrical storm (multiple ICD shocks for VF). Key discriminating findings: known Brugada syndrome, recurrent VF despite ICD, hemodynamically stable. The question asks for pharmacologic suppression of the arrhythmia. Isoproterenol (C) is the established acute treatment for Brugada electrical storm. It increases heart rate and enhances calcium current, normalizing repolarization abnormalities and suppressing VF. This is well-documented in Brugada management literature. Option A (Amiodarone) is contraindicated as it can worsen Brugada pattern through sodium channel blockade. Option B (Lidocaine) is a sodium channel blocker that can exacerbate Brugada ECG changes. Option D (Procainamide) is similarly contraindicated as a sodium channel blocker. Option E (Metoprolol) is contraindicated as beta-blockers can unmask or worsen Brugada pattern. The keyed answer is uniquely defensible based on established Brugada syndrome management principles. No logical flaws or medical inaccuracies present. The item tests appropriate knowledge of channelopathy-specific arrhythmia management. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 40-year-old male with Brugada syndrome in electrical storm (multiple ICD shocks for VF). Key discriminating findings: known Brugada syndrome, recurrent VF despite ICD, hemodynamically stable. The question asks for pharmacologic suppression of the arrhythmia. Isoproterenol (C) is the established acute treatment for Brugada electrical storm. It increases heart rate and enhances calcium current, normalizing repolarization abnormalities and suppressing VF. This is well-documented in Brugada management literature. Option A (Amiodarone) is contraindicated as it can worsen Brugada pattern through sodium channel blockade. Option B (Lidocaine) is a sodium channel blocker that can exacerbate Brugada ECG changes. Option D (Procainamide) is similarly contraindicated as a sodium channel blocker. Option E (Metoprolol) is contraindicated as beta-blockers can unmask or worsen Brugada pattern. The keyed answer is uniquely defensible based on established Brugada syndrome management principles. No logical flaws or medical inaccuracies present. The item tests appropriate knowledge of channelopathy-specific arrhythmia management. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-007", "question": "A 32-year-old female presents with subacute confusion, bilateral hearing loss, and visual field deficits. MRI brain shows multiple T2 hyperintense lesions in the corpus callosum ('snowballs') and periventricular white matter. Fluorescein angiography reveals multiple branch retinal artery occlusions (BRAO). CSF shows mild pleocytosis and elevated protein but no oligoclonal bands. What is the most likely diagnosis?", "options": ["Multiple Sclerosis", "CADASIL", "Susac Syndrome", "Primary CNS Angiitis", "Mitochondrial Encephalomyopathy (MELAS)"], "answer": "C", "answer_index": 2, "explanation": "Susac Syndrome is a rare autoimmune endotheliopathy characterized by the clinical triad of encephalopathy, branch retinal artery occlusions (BRAO), and sensorineural hearing loss. The MRI finding of 'snowball' lesions in the corpus callosum is highly characteristic. It is often misdiagnosed as MS, but the presence of BRAO and callosal lesions (rather than callososeptal interface lesions) distinguishes it.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a young woman with the classic triad of Susac syndrome: encephalopathy (subacute confusion), branch retinal artery occlusions (BRAO on fluorescein angiography), and bilateral sensorineural hearing loss. The MRI finding of 'snowball' lesions in the corpus callosum is pathognomonic for Susac syndrome. Key discriminating findings include: (1) the complete clinical triad, (2) characteristic corpus callosum lesions, (3) BRAO on angiography, and (4) absence of oligoclonal bands (helps exclude MS). Multiple Sclerosis (A) typically shows oligoclonal bands and callososeptal interface lesions rather than central corpus callosum 'snowballs,' and BRAO is not a feature. CADASIL (B) presents with recurrent strokes and migraine in patients with family history, not the Susac triad. Primary CNS Angiitis (D) would show vessel wall enhancement and typically more severe CSF abnormalities. MELAS (E) presents with stroke-like episodes, lactic acidosis, and different imaging patterns. The stem provides sufficient discriminating features to identify Susac syndrome uniquely. No logical flaws or medical inaccuracies detected. Minimal fix: None needed; item is well-constructed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a young woman with the classic triad of Susac syndrome: encephalopathy (subacute confusion), branch retinal artery occlusions (BRAO on fluorescein angiography), and bilateral sensorineural hearing loss. The MRI finding of 'snowball' lesions in the corpus callosum is pathognomonic for Susac syndrome. Key discriminating findings include: (1) the complete clinical triad, (2) characteristic corpus callosum lesions, (3) BRAO on angiography, and (4) absence of oligoclonal bands (helps exclude MS). Multiple Sclerosis (A) typically shows oligoclonal bands and callososeptal interface lesions rather than central corpus callosum 'snowballs,' and BRAO is not a feature. CADASIL (B) presents with recurrent strokes and migraine in patients with family history, not the Susac triad. Primary CNS Angiitis (D) would show vessel wall enhancement and typically more severe CSF abnormalities. MELAS (E) presents with stroke-like episodes, lactic acidosis, and different imaging patterns. The stem provides sufficient discriminating features to identify Susac syndrome uniquely. No logical flaws or medical inaccuracies detected. Minimal fix: None needed; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-008", "question": "A 29-year-old male who has sex with men presents with severe proctitis, tenesmus, and rectal bleeding. Rectal swab NAAT is positive for *Chlamydia trachomatis*. He was treated with Doxycycline 100 mg BID for 7 days with no improvement. His partner recently returned from Europe. Which of the following is the most appropriate management?", "options": ["Repeat Doxycycline 100 mg BID for 7 days", "Azithromycin 1 g single dose", "Ceftriaxone 500 mg IM single dose", "Extend Doxycycline 100 mg BID to complete a 21-day course", "Moxifloxacin 400 mg daily for 14 days"], "answer": "D", "answer_index": 3, "explanation": "Severe proctitis in MSM with a positive Chlamydia test should raise suspicion for Lymphogranuloma Venereum (LGV), caused by L1, L2, or L3 serovars. LGV requires a prolonged course of doxycycline (21 days) compared to non-LGV chlamydia (7 days). Standard treatment failure and severe symptoms (bleeding/tenesmus) strongly support a diagnosis of LGV.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes severe proctitis with tenesmus and rectal bleeding in an MSM patient with positive C. trachomatis NAAT who failed standard 7-day doxycycline therapy. Key discriminating findings: (1) severe invasive proctitis symptoms (bleeding, tenesmus), (2) treatment failure with standard 7-day doxycycline, (3) MSM population, (4) partner's recent European travel (LGV endemic). These clues strongly suggest Lymphogranuloma Venereum (LGV serovars L1-L3) rather than non-LGV urogenital chlamydia. LGV requires extended 21-day doxycycline per CDC guidelines. Option D (extend to 21 days) is the correct management. Alternative assessment: A (repeat 7 days) ignores treatment failure and LGV likelihood; B (azithromycin single dose) is inadequate for LGV and inferior to doxycycline; C (ceftriaxone) treats gonorrhea, not chlamydia; E (moxifloxacin) is not first-line for LGV. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent, reflecting current CDC/guideline recommendations for LGV management. Minimal fix: None needed; item is well-constructed and unambiguous.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes severe proctitis with tenesmus and rectal bleeding in an MSM patient with positive C. trachomatis NAAT who failed standard 7-day doxycycline therapy. Key discriminating findings: (1) severe invasive proctitis symptoms (bleeding, tenesmus), (2) treatment failure with standard 7-day doxycycline, (3) MSM population, (4) partner's recent European travel (LGV endemic). These clues strongly suggest Lymphogranuloma Venereum (LGV serovars L1-L3) rather than non-LGV urogenital chlamydia. LGV requires extended 21-day doxycycline per CDC guidelines. Option D (extend to 21 days) is the correct management. Alternative assessment: A (repeat 7 days) ignores treatment failure and LGV likelihood; B (azithromycin single dose) is inadequate for LGV and inferior to doxycycline; C (ceftriaxone) treats gonorrhea, not chlamydia; E (moxifloxacin) is not first-line for LGV. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent, reflecting current CDC/guideline recommendations for LGV management. Minimal fix: None needed; item is well-constructed and unambiguous.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-009", "question": "A 70-year-old man is evaluated for macrocytic anemia (MCV 105), thrombocytopenia, and recurrent inflammation of the ear and nose cartilage. He also has pulmonary infiltrates. Bone marrow biopsy demonstrates hypercellularity with vacuolization of myeloid and erythroid precursor cells. Genetic sequencing identifies a somatic mutation in *UBA1*. What is the diagnosis?", "options": ["Relapsing Polychondritis", "Myelodysplastic Syndrome (MDS)", "VEXAS Syndrome", "Sweet Syndrome", "Granulomatosis with Polyangiitis"], "answer": "C", "answer_index": 2, "explanation": "VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described disorder caused by somatic mutations in *UBA1*. It connects inflammatory features (polychondritis, vasculitis, infiltrates) with hematologic features (macrocytic anemia, vacuoles in marrow precursors). While it mimics relapsing polychondritis, the presence of marrow vacuoles and the *UBA1* mutation defines VEXAS.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem provides highly discriminating clues: (1) macrocytic anemia with thrombocytopenia, (2) relapsing polychondritis features (ear/nose cartilage inflammation), (3) pulmonary infiltrates, (4) bone marrow hypercellularity with characteristic vacuolization of myeloid/erythroid precursors, and (5) somatic UBA1 mutation. These findings collectively define VEXAS syndrome, a recently described autoinflammatory disorder that bridges hematologic and inflammatory manifestations. Option C is the unique best answer because the UBA1 mutation is pathognomonic for VEXAS. Option A (relapsing polychondritis) explains the cartilage inflammation but not the hematologic findings or UBA1 mutation. Option B (MDS) could explain cytopenias and marrow changes but not the inflammatory features or specific vacuolization pattern with UBA1 mutation. Option D (Sweet syndrome) presents with neutrophilic dermatosis, not polychondritis or this marrow picture. Option E (GPA) causes pulmonary-renal vasculitis but not polychondritis or these specific marrow findings. The item is logically valid with strong discriminating power. Medical accuracy is excellent; VEXAS is well-characterized in recent literature with these exact features. Minimal fix: None needed; item is well-constructed and unambiguous.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem provides highly discriminating clues: (1) macrocytic anemia with thrombocytopenia, (2) relapsing polychondritis features (ear/nose cartilage inflammation), (3) pulmonary infiltrates, (4) bone marrow hypercellularity with characteristic vacuolization of myeloid/erythroid precursors, and (5) somatic UBA1 mutation. These findings collectively define VEXAS syndrome, a recently described autoinflammatory disorder that bridges hematologic and inflammatory manifestations. Option C is the unique best answer because the UBA1 mutation is pathognomonic for VEXAS. Option A (relapsing polychondritis) explains the cartilage inflammation but not the hematologic findings or UBA1 mutation. Option B (MDS) could explain cytopenias and marrow changes but not the inflammatory features or specific vacuolization pattern with UBA1 mutation. Option D (Sweet syndrome) presents with neutrophilic dermatosis, not polychondritis or this marrow picture. Option E (GPA) causes pulmonary-renal vasculitis but not polychondritis or these specific marrow findings. The item is logically valid with strong discriminating power. Medical accuracy is excellent; VEXAS is well-characterized in recent literature with these exact features. Minimal fix: None needed; item is well-constructed and unambiguous.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-010", "question": "A 35-year-old female undergoes a cone biopsy for CIN 3. Pathology reveals invasive squamous cell carcinoma with 2 mm depth of invasion and 5 mm horizontal spread. Lymphovascular space invasion (LVSI) is extensively present. Margins are negative. Imaging shows no lymphadenopathy. She desires future fertility. According to NCCN guidelines, what is the recommended management?", "options": ["Simple trachelectomy", "Radical trachelectomy with pelvic lymph node assessment", "Conization with negative margins is sufficient", "Simple hysterectomy", "Pelvic radiation therapy"], "answer": "B", "answer_index": 1, "explanation": "The patient has Stage IA1 cervical cancer (invasion <= 3mm). However, the presence of Lymphovascular Space Invasion (LVSI) significantly increases the risk of lymph node metastasis and recurrence. Therefore, simple excision (cone) or simple trachelectomy/hysterectomy is insufficient. The recommended management for fertility preservation in IA1 with LVSI is radical trachelectomy with pelvic lymph node assessment (sentinel node or dissection).", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best answer. Key stem clues: 35-year-old desiring fertility, CIN 3 cone biopsy showing invasive SCC with 2mm depth, 5mm horizontal spread, extensive LVSI present, negative margins, no lymphadenopathy. The vignette describes Stage IA1 cervical cancer (≤3mm depth, ≤7mm horizontal). The critical discriminator is extensive LVSI. Per NCCN guidelines, Stage IA1 WITH LVSI is treated similarly to IA2 for fertility-sparing approaches. However, the extensive LVSI and desire for fertility create tension. NCCN guidelines for IA1 with LVSI typically recommend either modified radical hysterectomy with lymph node assessment OR, if fertility desired and LVSI focal, potentially radical trachelectomy. The term 'extensive' LVSI is problematic - extensive LVSI generally contraindicates fertility-sparing surgery due to high recurrence risk. Most guidelines consider extensive LVSI a relative contraindication to trachelectomy. The best answer should be D (simple hysterectomy) or modified radical hysterectomy, as extensive LVSI makes radical trachelectomy inappropriate. The item is miskeyed because option B (radical trachelectomy) is contraindicated by extensive LVSI. Medical accuracy issue: conflating focal vs extensive LVSI management. Minimal fix: Change 'extensively present' to 'focally present' to make B defensible, or change key to D and remove fertility desire.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best answer. Key stem clues: 35-year-old desiring fertility, CIN 3 cone biopsy showing invasive SCC with 2mm depth, 5mm horizontal spread, extensive LVSI present, negative margins, no lymphadenopathy. The vignette describes Stage IA1 cervical cancer (≤3mm depth, ≤7mm horizontal). The critical discriminator is extensive LVSI. Per NCCN guidelines, Stage IA1 WITH LVSI is treated similarly to IA2 for fertility-sparing approaches. However, the extensive LVSI and desire for fertility create tension. NCCN guidelines for IA1 with LVSI typically recommend either modified radical hysterectomy with lymph node assessment OR, if fertility desired and LVSI focal, potentially radical trachelectomy. The term 'extensive' LVSI is problematic - extensive LVSI generally contraindicates fertility-sparing surgery due to high recurrence risk. Most guidelines consider extensive LVSI a relative contraindication to trachelectomy. The best answer should be D (simple hysterectomy) or modified radical hysterectomy, as extensive LVSI makes radical trachelectomy inappropriate. The item is miskeyed because option B (radical trachelectomy) is contraindicated by extensive LVSI. Medical accuracy issue: conflating focal vs extensive LVSI management. Minimal fix: Change 'extensively present' to 'focally present' to make B defensible, or change key to D and remove fertility desire.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}]